Pipeline of Key Proprietary Products

We have a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 Regulatory
ALKS 3831
Schizophrenia / Bipolar I Disorder*

ALKS 4230
Oncology (Intravenous Dosing)
Oncology (Subcutaneous Dosing)

Selective HDAC Inhibitors
Neurodegenerative Disorders (Orphan)
Neurodegenerative Disorders (Prevalent, Non-orphan)
*PDUFA target action date of NDA resubmission: June 1, 2021
Oncology CNS